

November 7, 2022

**VIA EDGAR**

U.S. Securities and Exchange Commission  
Office of Life Sciences  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549

Attn: Daniel Crawford  
Jason Drory  
Li Xiao  
Lynn Dicker

**Re: Acrivon Therapeutics, Inc.  
Registration Statement on Form S-1  
Registration No. 333-267911**

**Acceleration Request**

**Requested Date: November 9, 2022**

**Requested Time: 4:00 PM, Eastern Time**

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended (the "*Act*"), Morgan Stanley & Co. LLC, Jefferies LLC, Cowen and Company, LLC and Piper Sandler & Co., as representatives of the several underwriters, hereby join Acrivon Therapeutics, Inc. in requesting that the Securities and Exchange Commission (the "*Commission*") take appropriate action to cause the Registration Statement on Form S-1 (File No. 333-267911) (the "*Registration Statement*") to become effective on November 9, 2022, at 4:00 PM, Eastern Time, or as soon as practicable thereafter.

Pursuant to Rule 460 under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus, to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.

We have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, to the extent applicable.

*[Signature Page Follows]*

Very truly yours,

Morgan Stanley & Co. LLC

By: /s/ Chirag D. Surti

Name: Chirag D. Surti

Title: Vice President

Jefferies LLC

By: /s/ Dustin Tyner

Name: Dustin Tyner

Title: Managing Director

Cowen and Company, LLC

By: /s/ Bill Follis

Name: Bill Follis

Title: Managing Director

Piper Sandler & Co.

By: /s/ Paul Scansaroli

Name: Paul Scansaroli

Title: Managing Director

cc: Peter Blume-Jensen, M.D., Ph.D., Acrivon Therapeutics, Inc.  
Edwin M. O'Connor, Goodwin Procter LLP  
William A. Magioncalda, Goodwin Procter LLP  
Divakar Gupta, Cooley LLP  
Ryan S. Sansom, Cooley LLP  
Mark Ballantyne, Cooley LLP  
Katherine Denby, Cooley LLP

*[Signature Page to Acceleration Request]*